1. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. Jour Clin Oncol. 2011;29(24):3328-3330. The full practice guideline and additional information is available at Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays.
2. Burstein HJ, Mangu PB, Somerfield MR. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. Jour Clin Oncol. 2011;29(24):3328-3330.
3. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S. Ovarian Cancer Trial Group. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician’s choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs. 2007;18(9):1093-1101.
4. d’Amato TA, Pettiford BL, Schuchert MJ, et al. Survival Among Patients With Platinum Resistant, Locally Advanced Non-Small Cell Lung Cancer treated With Platinum-Based Systemic Therapy. Ann Surg Oncol. 20;16(10):2848-2855.
5. Einenkel J, Wuttke P, Horn K. Should the extreme drug resistance assay fade into oblivion? Commentary on Karam AK, Chiang JW, Fung E, Nossov V and Karlan BY. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol. 2010;116(1)148-9.
6. Eltabbakh GH, Piver MS, Hempling RE, et al. Correlation Between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients With Epithelial Ovarian Cancer. Gynecol Oncol. 1998;70(3):392-397.
7. Eltabbakh GH. Extreme Drug Resistance Assay and Response to Chemotherapy in Patients with Primary Peritoneal Carcinoma. Jour Surg Oncol. 2000;73(3):148-152.
8. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Current Oncol. 2007;14(5):195-208.
9. Geisler JP, Linnemeier GC, Thomas AJ, Manahan KJ. Extreme drug resistance is common after prior exposure to Paclitaxel. Gynecol Oncol. 2007;106(3):538-540.
10. Haroun RI, Clatterbuck RE, Gibbons MC, et al. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens. Jour Neuro Oncol. 2002;58(2):115-123.
11. Herzog TJ, Fader AN, Fensterer JE, Gallion HH, Krivak TC, Coleman RL. A chemoresponse assay and survival in primary ovarian cancer. Jour Clinc Oncol. 2008;26(15):16522.
12. Holloway RW, Mehta RS. Finkler NJ, et al. Association between in Vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol. 2002;87(1):8-16.
13. Holloway RW. Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer. Gynecol Oncol. 2010;116(1):147-148.
14. Karam AK, Chiang JW, Fung E, Nossov V, Karlan BY. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol. 2009;114(2):246-252.
15. Kern DH, Weisenthal LM. Highly Specific Prediction of Antineoplastic Drug Resistance With an In Vitro Assay Using Suprapharmacologic Drug Exposures. Jour Natl Canc Instit. 1990;82(7):582-588.
16. Kim HS, Kim TJ, Chung HH, et al. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. Jour Cancer Res Clin Oncol. 2009;135(11):1513-1520.
17. Korn AM, Eddy DM. Chemotherapy Sensitivity and Resistance Assays. Blue Cross and Blue Shield Association Technology Evaluation Center. 2002;17(12):1-39
18. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol. 2003;189(5):1301-1307.
19. Marchionni L, Wilson RF, Marinopoulos SS, Wolff AC, Parmigiani G, Bass EB, Goodman SN. Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes. Evidence Reports/Technology Assessments No. 160. (Prepared by The Johns Hopkins University Evidence-based Practice Center under contract No. 290-02-0018). AHRQ Publication No. 08-E002. Rockville, MD: Agency for Healthcare Research and Quality. January 2008.
20. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int Jour Cancer. 2009;125(11): 2721-2727.
21. Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010;116(1):61-65.
22. Mehta RS, Bornstein R, Yu IR, et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Can Resear Treat. 2001;66(3):225-237.
23. Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. Jour of Neuro-Oncol. 2004;66(3):365-375.
24. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy Sensitivity and Resistance Assays: A Systematic Review. Jour Clin Oncol. 2004;22(17):3618-3630.
25. Schrag D, Garewal HS, Burstein HJ, Sampson DJ, Von Hoff DD, Somerfield MR. American Society of Clinical Oncology. Technology Assessment: Chemotherapy Sensitivity and Resistance Assays. Jour Clin Oncol. 2004;22(17):3631-3638.
26. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653): 1006-1110.